Cerenis Therapeutics, the biopharmaceutical HDL company developing CER-001, an engineered human apoA-I-containing pre-ß HDL mimetic for the treatment of cardiovascular disease, today announced the appointment of a new CMO and new Board Members and the leadership of a Phase II clinical CARAT study of CER-001 in post-Acute Coronary Syndrome (ACS) patients.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
